-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $292

Benzinga·04/16/2026 14:12:05
Listen to the news
B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $262 to $292.